Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study

• Published in: Cancers Vol. 14; no. 24; p. 6099
• Main Authors: Pellegrini, Ilaria, Drabbe, Cas, Grünhagen, Dirk J, Van de Sande, Michiel A J, de Haan, Jacco J, Keymeulen, Kristien B M I, Bonenkamp, Johannes J, Van der Graaf, Winette T A, Husson, Olga
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11.12.2022; MDPI
• Subjects: Breast cancer; Cancer; Cancer survivors; Care and treatment; Comorbidity; Comparative analysis; Data collection; Fear; Health aspects; Likert scale; Patient outcomes; Patients; Psychological aspects; Public health; Quality of life; Questionnaires; Relapse; Sarcoma; Statistical analysis; Survival; Tumors; Netherlands; follow-up; health-related quality of life; fear of cancer recurrence; sarcoma; survivors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14246099

Fear of cancer recurrence (FCR) is often reported as an unmet concern by cancer patients. The aim of our study was to investigate (1) the prevalence of FCR in sarcoma survivors; (2) the factors associated with a higher level of FCR; the relationship between (3) FCR and global health status and (4) FCR and use of follow-up care. A cross-sectional study was conducted among sarcoma survivors 2 to 10 years after diagnosis. Patients completed the Cancer Worry Scale (CWS), the global health status subscale of the EORTC QLQ-C30 and a custom-made questionnaire on follow-up care. In total, 1047 patients were included (response rate 55%). The prevalence of high FCR was 45%. Factors associated with high FCR were female sex with 1.6 higher odds (95% CI 1.22-2.25; = 0.001); having ≥1 comorbidities and receiving any treatment other than surgery alone with 1.5 (95% CI 1.07-2.05; = 0.017) and 1.4 (95% CI 1.06-1.98; = 0.020) higher odds, respectively. Patients on active follow-up had 1.7 higher odds (95% CI 1.20-2.61; = 0.004) and patients with higher levels of FCR scored lower on the global health status scale (72 vs. 83 ≤ 0.001). Severe FCR is common in sarcoma survivors and high levels are related to a decreased global health status. FCR deserves more attention in sarcoma survivorship, and structured support programs should be developed to deliver interventions in a correct and time adequate environment.